The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) (#HOPE4KIDNEY)

• ClinicalTrials.gov Identifier: NCT05820087
• Recruitment Status: Recruiting
• First Posted: April 19, 2023
• Last Update Posted: March 25, 2024
• Sponsor: HistoSonics, Inc.
• Information provided by (Responsible Party): HistoSonics, Inc.

Tracking Information

• First Submitted Date: April 6, 2023
• First Posted Date: April 19, 2023
• Last Update Posted Date: March 25, 2024
• Actual Study Start Date: January 4, 2024
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 18, 2023)

• Primary Effectiveness Endpoint - Primary technique efficacy defined as the percentage of targeted tumors that were successfully eliminated after a single histotripsy session as assessed by contrast enhanced MRI or CT at 90 days. [ Time Frame: 90 days Post Index Procedure ]
  Primary Effectiveness Endpoint
• Primary Safety Endpoint - Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the histotripsy procedure. [ Time Frame: 30 days Post Index Procedure ]
  Primary Safety Endpoint

Original Primary Outcome Measures (submitted: April 6, 2023)

• Primary Effectiveness Endpoint [ Time Frame: 90 days Post Index Procedure ]
  Primary technique efficacy defined as the percentage of targeted tumors that were successfully eliminated after a single histotripsy session as assessed by contrast enhanced MRI or CT at 90 days.
• Primary Safety Endpoint [ Time Frame: 30 days Post Index Procedure ]
  Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the histotripsy procedure.

Current Secondary Outcome Measures (submitted: April 18, 2023)

• Secondary Effectiveness Endpoint- Technical success demonstrating complete coverage of the targeted tumor as determined post-index procedure (≤36 hours) by contrast enhanced MRI or CT in subjects whom treatment was initiated. [ Time Frame: Up to 36 hours Post Index Procedure ]
  Secondary Effectiveness Endpoint - Technical success defined as completion of histotripsy treatment according to protocol and demonstrating complete coverage of the targeted tumor as determined post-index procedure (≤36 hours) by contrast enhanced MRI or CT in subjects whom treatment was initiated.
• Secondary Safety Endpoint - Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 90 days after the histotripsy procedure. [ Time Frame: 90 days Post Index Procedure ]
  Secondary Safety Endpoint

Original Secondary Outcome Measures (submitted: April 6, 2023)

• Secondary Effectiveness [ Time Frame: Up to 36 hours Post Index Procedure ]
  Technical success defined as completion of histotripsy treatment according to protocol and demonstrating complete coverage of the targeted tumor as determined post-index procedure (≤36 hours) by contrast enhanced MRI or CT in subjects whom treatment was initiated.
• Secondary Safety [ Time Frame: 90 days Post Index Procedure ]
  Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 90 days after the histotripsy procedure.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
• Official Title: The HistoSonics Edison System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY US)
• Brief Summary: The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
• Detailed Description: This trial is a prospective, multi-center, single-arm pivotal trial designed to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors. Data through 90 days for all enrolled subjects will be summarized in a primary analysis to be submitted for Regulatory Submission to the FDA. Additionally, subjects will be followed for five (5) years post-index procedure, with evaluations at the 14-day, 30-day, 90-day, 180-day and annual time points.
• Study Type: Interventional
• Study Phase: Not Applicable

Study Design

Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

This trial is a prospective, multi-center, single-arm.

Masking: None (Open Label)
Primary Purpose: Treatment

Condition

• Renal Cancer
• Tumor, Solid
• Kidney Cancer
• Tumor
• Tumor, Benign

Intervention

Device: HistoSonics Edison System

Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.

Other Name: Histotripsy

Study Arms

Experimental: HistoSonics Edison System

Intervention: Device: HistoSonics Edison System

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: April 6, 2023): 68
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 2029
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Subject is ≥22 years of age.
2. Subject has signed the Institutional Review Board (IRB) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
3. Subject is diagnosed with only one (1) non-metastatic solid renal mass ≤3cm confirmed via CT or MRI ≤30 days prior to the index procedure date.
4. Subject has had a biopsy to determine the type of tumor, ≥14 days prior to the index procedure.
5. Subject can tolerate general anesthesia.
6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2 at baseline screening.

7. Subject meets all the following functional criteria at ≤14 days prior to the planned index procedure date:

   • White Blood Count (WBC) ≥3,000/mm3 (≥3 10*9/L)
   • Absolute Neutrophil Count (ANC) ≥1,200/mm3 (≥1.2 10*9/L)
   • Hemoglobin (Hgb) ≥9 g/dL
   • Platelet count ≥100,000/mm3 (≥100 10*9/L)
   • White Blood Count (WBC) ≤5 hpf via urinalysis
   • Albumin ≤300 mg/g via urinalysis
8. Subject has an eGFR (Glomerular filtration rate) ≥45mL/min, ≤14 days prior to the planned index procedure date.
9. The tumor selected for histotripsy treatment must be ≤3cm in longest diameter.
10. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.

Exclusion Criteria:

1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
2. Subject is being actively treated in another pharmaceutical or device trial ≤30 days prior to planned index procedure date that may interfere with the primary endpoint(s).
3. Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
4. In the Investigator's opinion, the subject has co-morbid disease(s) or condition(s) that would cause undue risk and preclude safe use of the HistoSonics Edison System.
5. Subject is on dialysis, being considered for dialysis or has acute renal failure.
6. Subject has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or better from any adverse effects (except alopecia and neuropathy) related to previous therapy.
7. Subject has an International normalized ratio (INR) >1.5 or uncorrectable coagulopathy, (e.g., known von Willebrand disease, hemophilia, or on anticoagulants), on the planned index procedure date.
8. Subject is taking Aspirin (ASA) or NSAIDS ≤14 days prior to the planned index procedure date.
9. Subject has a life expectancy less than one (< 1) year.
10. In the investigator's opinion, histotripsy is not a treatment option for the subject.
11. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
12. Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, radiation).
13. Subject's targeted tumor is not treatable by the HistoSonics Edison System's working ranges (refer to User Guide).
14. In the investigator's opinion, the anticipated risks of intervention outweigh the potential benefits of the intervention.
15. Subject has bilateral kidney tumors or has a single functioning kidney.

16. Subject has a genetic predisposition to kidney cancer such as:

    • Von Hippel Lindau (VHL)
    • Hereditary Papillary Renal Carcinoma (HPRC)
    • Birt-Hogg-Dubé Syndrome (BHD)
    • Tuberous Sclerosis Complex (TSC)
    • Hereditary Leiomyomata's Renal Cell Carcinoma (HLRCC)
    • Reed's Syndrome
    • Succinate Dehydrogenase B Deficiency (SDHB)
    • BRCA 1 associated protein -1 (BAP1) Renal Cell Carcinoma
    • MITF predisposed Renal Cell Carcinoma
17. The targeted tumor is an angiomyolipoma.
18. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
19. The targeted tumor is not clearly visible with ultrasound, MRI or CT.
20. Targeted tumor with adequate margin overlaps the renal pelvis, main renal vessel, ureter, or other vital structure.
21. The treatment of the tumor will not allow an adequate margin (as determined by the investigator).

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 22 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Amber Dickson; 612-351-0361; amber.dickson@histosonics.com

Contact: Zoe Secord; 612-351-0361; zoe.secord@histosonics.com

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT05820087
• Other Study ID Numbers: CSP2083
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: HistoSonics, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: HistoSonics, Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: HistoSonics, Inc.
• Verification Date: March 2024